2. Measurable metastatic disease that can be monitored throughout the course of the study participation per RECIST 1.1 (refer to Appendix C)

3. Subjects who are candidates for a first-line therapy initiating with sunitinib

4. Time from diagnosis to treatment < 1 year

5. Karnofsky performance status (KPS) ≥ 80%

6. Life expectancy of 6 months or greater

7. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0

8. Adequate hematologic, renal, hepatic, and coagulation function

9. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug

10. Normal ECG or clinically non-significant finding(s) at Screening

11. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study

We are a Cancer Social Network, Resource Directory & Education Hub supporting all those affected by cancer. knowcancer.com is intended to be solely for informational purposes and should not be a substitute for professional medical advice, diagnosis or treatment.